Cargando…

The challenges of COVID‐19 Delta variant: Prevention and vaccine development

Several SARS‐CoV‐2 variants have emerged since the pandemic, bringing about a renewed threat to the public. Delta variant (B.1.617.2) was first detected in October 2020 in India and was characterized as variants of concern (VOC) by WHO on May 11, 2021. Delta variant rapidly outcompeted other variant...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xuemei, He, Cai, Hong, Weiqi, Zhang, Kang, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661803/
https://www.ncbi.nlm.nih.gov/pubmed/34909755
http://dx.doi.org/10.1002/mco2.95
_version_ 1784613390522515456
author He, Xuemei
He, Cai
Hong, Weiqi
Zhang, Kang
Wei, Xiawei
author_facet He, Xuemei
He, Cai
Hong, Weiqi
Zhang, Kang
Wei, Xiawei
author_sort He, Xuemei
collection PubMed
description Several SARS‐CoV‐2 variants have emerged since the pandemic, bringing about a renewed threat to the public. Delta variant (B.1.617.2) was first detected in October 2020 in India and was characterized as variants of concern (VOC) by WHO on May 11, 2021. Delta variant rapidly outcompeted other variants to become the dominant circulating lineages due to its clear competitive advantage. There is emerging evidence of enhanced transmissibility and reduced vaccine effectiveness (VE) against Delta variant. Therefore, it is crucial to understand the features and phenotypic effects of this variant. Herein, we comprehensively described the evaluation and features of Delta variant, summarized the effects of mutations in spike on the infectivity, transmission ability, immune evasion, and provided a perspective on efficient approaches for preventing and overcoming COVID‐19.
format Online
Article
Text
id pubmed-8661803
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86618032021-12-10 The challenges of COVID‐19 Delta variant: Prevention and vaccine development He, Xuemei He, Cai Hong, Weiqi Zhang, Kang Wei, Xiawei MedComm (2020) Perspectives Several SARS‐CoV‐2 variants have emerged since the pandemic, bringing about a renewed threat to the public. Delta variant (B.1.617.2) was first detected in October 2020 in India and was characterized as variants of concern (VOC) by WHO on May 11, 2021. Delta variant rapidly outcompeted other variants to become the dominant circulating lineages due to its clear competitive advantage. There is emerging evidence of enhanced transmissibility and reduced vaccine effectiveness (VE) against Delta variant. Therefore, it is crucial to understand the features and phenotypic effects of this variant. Herein, we comprehensively described the evaluation and features of Delta variant, summarized the effects of mutations in spike on the infectivity, transmission ability, immune evasion, and provided a perspective on efficient approaches for preventing and overcoming COVID‐19. John Wiley and Sons Inc. 2021-10-19 /pmc/articles/PMC8661803/ /pubmed/34909755 http://dx.doi.org/10.1002/mco2.95 Text en © 2021 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspectives
He, Xuemei
He, Cai
Hong, Weiqi
Zhang, Kang
Wei, Xiawei
The challenges of COVID‐19 Delta variant: Prevention and vaccine development
title The challenges of COVID‐19 Delta variant: Prevention and vaccine development
title_full The challenges of COVID‐19 Delta variant: Prevention and vaccine development
title_fullStr The challenges of COVID‐19 Delta variant: Prevention and vaccine development
title_full_unstemmed The challenges of COVID‐19 Delta variant: Prevention and vaccine development
title_short The challenges of COVID‐19 Delta variant: Prevention and vaccine development
title_sort challenges of covid‐19 delta variant: prevention and vaccine development
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661803/
https://www.ncbi.nlm.nih.gov/pubmed/34909755
http://dx.doi.org/10.1002/mco2.95
work_keys_str_mv AT hexuemei thechallengesofcovid19deltavariantpreventionandvaccinedevelopment
AT hecai thechallengesofcovid19deltavariantpreventionandvaccinedevelopment
AT hongweiqi thechallengesofcovid19deltavariantpreventionandvaccinedevelopment
AT zhangkang thechallengesofcovid19deltavariantpreventionandvaccinedevelopment
AT weixiawei thechallengesofcovid19deltavariantpreventionandvaccinedevelopment
AT hexuemei challengesofcovid19deltavariantpreventionandvaccinedevelopment
AT hecai challengesofcovid19deltavariantpreventionandvaccinedevelopment
AT hongweiqi challengesofcovid19deltavariantpreventionandvaccinedevelopment
AT zhangkang challengesofcovid19deltavariantpreventionandvaccinedevelopment
AT weixiawei challengesofcovid19deltavariantpreventionandvaccinedevelopment